查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853776

新冠肺炎疫苗市場：依疫苗技術、劑量方案、給藥途徑、包裝類型、通路、最終用戶和採購模式分類－2025-2032年全球預測

COVID-19 Vaccines Market by Vaccine Technology, Dosage Regimen, Application Route, Packaging Type, Distribution Channel, End User, Procurement Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，新冠肺炎疫苗市場規模將達到 5,435.7 億美元，複合年成長率為 10.92%。

關鍵市場統計數據
基準年 2024 2371.2億美元
預計年份：2025年 2631億美元
預測年份 2032 5435.7億美元
複合年成長率 (%) 10.92%

為正在轉型中的新冠肺炎疫苗生態系統提供權威指導，強調科學加速、監管調整和系統層面的韌性。

全球應對新冠疫情的行動永久再形成了疫苗研發模式、公共衛生運作以及整個醫療生態系統的商業性考量。過去幾年，科學發現以前所未有的速度發展，催生了新型疫苗平台與傳統方法並存的局面。同時，監管的緊迫性和嚴格的安全監督之間的相互作用，為適應性臨床試驗設計和滾動申請途徑創造了新的先例。這些轉變改變了製造商、付款者和醫療服務提供者評估風險、分配資源和確定投資優先順序的方式。

在此背景下，供應鏈韌性已成為一項策略重點，涵蓋互聯互通的低溫運輸物流、原料採購和製造外包。公共衛生需求模式不斷演變，疫苗接種率、加強針接受率以及多樣化的需求都促使計畫進行調整。市場參與企業和現有企業都必須在科學創新與複雜的配送需求以及日益嚴格的公眾監督並存的環境中運作。因此，免疫產業的下一階段將著重於可擴展的生產、透明的傳播策略以及政策協調，以維持免疫計畫的持續並維護公眾信任。

科學基礎的分化、供應鏈的演變以及公眾行為如何從根本上重塑新冠疫苗接種的戰略方法

新冠疫苗接種領域正經歷多項變革性轉變，這些轉變持續影響各相關人員的策略決策。傳訊RNA技術的科學成熟不僅展現了其快速應對新出現的變異株的能力，也影響未來疫苗研發平台的選擇。同時，蛋白質次單元製劑的改進，包括最佳化的佐劑系統，為需要不同安全性和反應原性特徵的人提供了更多選擇。這些並行發展催生了更多元化的產品平臺，並為生產商和採購商拓寬了策略選擇。

在營運層面，分銷網路進行了調整，以平衡大規模疫苗宣傳活動與透過臨床和藥房管道進行的有針對性的常規供應。政策框架也不斷發展，以適應疫情時代的緊急準備，同時逐步將經驗教訓融入標準監管流程。供應鏈組織透過與委託製造和低溫運輸物流供應商建立策略夥伴關係得到改善，但在專業投入和產能瓶頸方面仍存在薄弱環節。此外，公眾對加強針和兒童免疫接種的態度和行為動態持續影響著需求訊號，因此需要製定一項持續的參與策略，將透明的證據溝通與量身定做的接種方案相結合。

2025 年的關稅環境將鼓勵疫苗價值鏈的採購多元化、供應鏈風險降低以及對國內製造業的投資。

2025年關稅及相關貿易措施的實施，使疫苗採購和分發的動態更加複雜，影響了成本結構、籌資策略和產業計畫。關稅變化影響了價值鏈上的各個環節，包括無菌生產所需的特殊原料、一次性生產組件和包裝用品。這些調整促使採購團隊重新評估其供應商組合，探索替代籌資策略，並專注於近岸外包和區域製造夥伴關係，以降低跨境成本波動帶來的風險。

為因應關稅風險加劇，供應鏈管理者加強了供應商資質認證流程，並尋求合約保障以確保生產連續性。低溫運輸物流供應商和契約製造製造商調整了定價模式，以反映跨境運輸帶來的成本增加和行政負擔加重。同時，醫療系統和公共採購機構也重新評估了採購模式，更嚴格地審查了總到岸成本、前置作業時間和供應保障。關稅情勢也促使企業投資於國內灌裝和包裝產能，並建立優先考慮區域多元化的夥伴關係，從而提升戰略韌性，但也需要資金配置和長期規劃。

一種多維度細分觀點，它將平台科學、管理策略、交付路線、包裝、分銷管道、終端用戶人口統計和採購模式聯繫起來

精細化的細分框架明確了產品開發、交付策略和商業性方法必須如何調整才能滿足不同的需求。基於疫苗技術，區分去活化疫苗、mRNA疫苗和蛋白質次單元平台至關重要，因為每種途徑的開發時間、生產規模和低溫運輸能力各不相同。基於接種方案，加強針、單劑和兩劑等策略的差異會影響專案設計、依從性，並改變採購團隊的供應週期。基於給藥途徑，肌肉注射或鼻腔給藥的選擇決定了給藥基礎設施的需求，並可能影響特定族群的接種率。

此外，基於包裝類型（預填充式注射器與管瓶）的細分會對營運產生影響，包括浪費率、大型診所的給藥速度以及低溫運輸數量規劃。診所、醫院和藥局等分銷管道的細分凸顯了針對不同管道製定合作模式和報銷方案的必要性。最終使用者分為青少年、成人和兒童群體，需要客製化臨床證據包、安全溝通和給藥策略才能實現目標。最後，政府採購和私人採購模式的細分會影響價格談判、合約結構和存取途徑，從而影響製造商如何建立商業報價和管理管道夥伴關係。綜合這些細分，相關人員可以將產品屬性與實際營運情況和人群需求相匹配。

不同的區域政策框架、生產能力和分銷模式如何影響針對新冠疫苗取得和計畫實施的有針對性方法

區域動態持續對疫苗政策、分發基礎設施和商業性模式產生重大影響，並認知到這些差異對於制定有效策略至關重要。在美洲，大規模的公共採購項目與透過臨床和藥房管道產生的大量私人需求並存，從而形成了雙軌分發模式，該模式強調靈活的供應合約和強大的低溫運輸物流。法規環境傾向於沿用現有的緊急核准機制，並逐步調整以規範上市後監測實踐，而公共衛生宣傳活動則日益重視加強推廣和兒童接種策略。

歐洲、中東和非洲的監管環境更為多樣化，有些市場擁有先進的監管體系，而有些市場則面臨產能限制。這種多樣性支持將區域製造地、有針對性的推廣計劃和資金籌措機制相結合的策略，以改善疫苗的可及性。官民合作關係和國際採購聯盟在解決不公平現象和物流缺口方面發揮著至關重要的作用。在亞太地區，快速擴大生產規模的能力、不斷發展的契約製造生態系統以及多樣化的監管時間表，既為市場准入帶來了機遇，也帶來了挑戰。亞太地區的製藥公司優先考慮供應可靠性、價格競爭力以及支持大規模疫苗宣傳活動的能力，同時還要應對不斷變化的區域監管預期和分銷模式。政策制定者、製造商和服務提供者之間的合作對於在任何地區實施有效的疫苗計劃至關重要。

疫苗研發商、委託製造和物流合作夥伴的策略行動凸顯了協作、模組化產能擴張和通路多元化。

新冠疫苗領域的企業正採取多種策略性舉措，涵蓋平台創新、配方改進、產能驅動型夥伴關係以及商業管道多元化等。領先的生物製藥公司持續投資於下一代疫苗平台和佐劑系統，以擴大目標族群並提升安全性和耐受性。同時，受託製造廠商和低溫運輸物流專家正加強與疫苗研發者的合作，以提高填充和包裝效率，並緩解先前阻礙疫苗快速部署的瓶頸。

策略合作已成為主導趨勢，涵蓋臨床研究型大學、生物技術創新者和全球分銷合作夥伴的聯盟，在控制成本和風險的同時，加速了候選藥物的研發進程。一些公司優先採用模組化生產設計，以實現產品類型之間的快速切換；而另一些公司則投資建設區域生產中心，以減少貿易中斷的影響。商業策略日益將政府直接合約與藥局和診所管道結合，並輔以有針對性的教育宣傳活動，以消除消費者的疑慮。總而言之，競爭格局有利於那些能夠將科學研究敏捷性、營運擴充性以及值得信賴、透明的相關人員溝通相結合的機構。

疫苗相關人員可採取切實可行的策略性舉措，以提高生產彈性、低溫運輸透明度、監管參與度以及針對特定管道的准入方式。

產業領導者可以透過將策略投資與營運實際情況和公共衛生目標結合，加速產生影響。首先，優先發展能夠適應多種平台和劑量配置的靈活生產能力，可以縮短新型製劑的研發時間，並支援對新出現的變體做出快速反應。其次，透過數位化追蹤和整合物流，增強端對端低溫運輸的可視性，夥伴關係最大限度地減少浪費，並改善分配決策，尤其是在儲存基礎設施有限的環境中。第三，加強與監管機構的溝通，並專注於特定人群（例如青少年和兒童）的獨特證據要求，可以簡化核准途徑，並提高專案的可信度。

同時，採取差異化的管道策略，充分考慮診所、醫院和藥房的不同角色，既能確保更廣泛的疫苗取得途徑，又能滿足地方政府的偏好。投資量身定做的風險溝通和社區參與項目，也有助於提高加強針的接種率，並保持疫苗偏好。最後，探索將長期供應承諾與私人採購選項結合的採購結構，既能支持公共衛生目標，也能保障商業性永續性。這些策略共同作用，可以增強疫苗接種的韌性，促進公平獲取，並為疫苗利益相關人員創造更可預測的營運環境。

採用嚴謹的混合方法研究途徑，整合相關人員訪談、監管和臨床證據審查以及供應鏈案例研究三角驗證。

本研究整合了一手和二手資料，建構了新冠疫苗領域的全貌。一手資料包括對生產製造、物流、監管事務和公共衛生管理等各領域相關人員的結構化訪談，從而獲得關於營運挑戰和策略應對的第一手觀點。二手資料包括同儕審查文獻、官方監管文件、臨床試驗註冊資訊和產業技術報告，以佐證事實並交叉檢驗結論。透過供應鏈流程圖和案例研究，對分銷和採購實踐數據進行三角驗證，以突出實際應用中的經驗教訓。

本研究採用質性主題分析與情境比較評估結合的分析方法，旨在發現風險並識別因應策略。調查方法強調資訊來源的透明度和方法的可複製性，包括清晰記錄訪談通訊協定、二手資料的納入標準以及用於綜合分析結果的框架。在適當情況下，研究還納入了敏感度分析，以評估貿易政策變化、衍生方案的出現以及公眾接受度如何影響營運重點。這種混合方法的研究成果既反映了實證證據，也體現了實踐者的觀點。

一份全面、具有前瞻性的審查報告強調了科學創新、營運韌性和支持性政策對於疫苗計畫長期成功的重要性。

隨著國際社會逐漸走出疫情初期緊急階段，新冠疫苗生態系統正步入一個更為複雜和成熟的時期，科學創新、卓越營運和政策一致性將決定長期的成效。新型平台、不斷演進的給藥策略和多樣化的交付模式相互作用，為提高人群保護水平提供了多種途徑，同時也能解決公平性和可及性方面的問題。然而，要抓住這些機遇，需要持續投資於可擴展的生產、更聰明的採購方式以及持續的公眾參與，以維持公眾信任和提高疫苗接種率。

展望未來，各組織能否成功很可能取決於其將科學進步與具有韌性的供應鏈和適應性強的監管策略相結合的能力。積極管理關稅和貿易風險、投資模組化生產能力並採取因地制宜策略的相關人員，將更有能力提供可靠的疫苗供應。最終，該領域的進展將取決於公共和私營相關人員攜手合作，共同解決問題，協調獎勵，共用資源，並優先考慮能夠最大限度造福公眾健康的干涉措施。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大針對新出現的SARS-CoV-2變種的二價和多效價疫苗配方，以提高免疫覆蓋率
  • 鼻腔和黏膜疫苗候選藥物在預防感染和提高患者依從性方面變得越來越重要。
  • 生物技術新興企業與大型製藥公司建立策略夥伴關係，以加速擴大疫苗生產能力
  • 下一代新冠疫苗在全球主要市場獲得有條件核准，這是監管的里程碑。
  • 投資人對耐熱mRNA疫苗平台的興趣日益濃厚，這類平台可望促進疫苗在資源匱乏地區的分發。
  • 隨著免疫特徵和劑量指南的變化，兒科和孕產婦疫苗接種計劃越來越受到重視。
  • 制定一項泛冠狀病毒疫苗研究舉措，旨在廣泛預防未來通用感染疾病的爆發

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依疫苗技術分類的COVID-19疫苗市場

  • 惰性
  • mRNA
  • 蛋白質次單元
    • 添加佐劑
    • 非佐劑

9. 新冠疫苗市場依劑量方案分類

  • 加強劑量
  • 單一劑量
  • 兩劑疫苗

10. 新冠疫苗市場依給藥途徑分類

  • 肌肉內注射
  • 鼻內

第11章：按包裝類型分類的COVID-19疫苗市場

  • 預填充式注射器
  • 管瓶

12. 新冠疫苗市場按分銷管道分類

  • 診所
  • 醫院
  • 藥局

第13章：按最終用戶分類的 COVID-19 疫苗市場

  • 青春期
  • 成人
  • 孩子

14. 新冠疫苗市場採購模式

  • 政府採購
  • 私人購買

15. 各地區的 COVID-19 疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：按群體分類的新冠疫苗市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：各國新冠疫苗市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Moderna, Inc.
    • AstraZeneca PLC
    • Johnson & Johnson Services Inc.
    • China National Pharmaceutical Group Co., Ltd.
    • Sinovac Biotech Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Novavax, Inc.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market is projected to grow by USD 543.57 billion at a CAGR of 10.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 237.12 billion
Estimated Year [2025] USD 263.10 billion
Forecast Year [2032] USD 543.57 billion
CAGR (%) 10.92%

An authoritative orientation to the transformed COVID-19 vaccine ecosystem highlighting scientific acceleration, regulatory adaptation, and system-level resilience

The global response to COVID-19 has permanently reshaped vaccine development paradigms, public health operations, and commercial considerations across the healthcare ecosystem. Over the past years, scientific discovery accelerated at an unprecedented pace, catalyzing novel vaccine platforms alongside traditional approaches. Simultaneously, the interplay between regulatory urgency and rigorous safety oversight created new precedents for adaptive clinical trial design and rolling submission pathways. These shifts have changed how manufacturers, payers, and providers evaluate risk, allocate resources, and prioritize investments.

Against this backdrop, supply chain resilience emerged as a strategic priority, intersecting cold chain logistics, raw material sourcing, and contract manufacturing capacity. Public health demand patterns evolved as populations experienced heterogeneous rates of vaccine uptake, booster acceptance, and variant-driven needs, prompting programmatic adjustments. Market entrants and incumbents alike must now operate within a landscape where scientific innovation coexists with complex distribution requirements and heightened public scrutiny. Consequently, the industry's next phase emphasizes scalable manufacturing, transparent communication strategies, and policy alignment to sustain immunization programs and maintain public trust.

How scientific platform diversification, supply chain evolution, and public behavior are fundamentally reshaping strategic approaches to COVID-19 vaccination delivery

The landscape of COVID-19 vaccination is defined by several transformative shifts that continue to influence strategic decision-making across stakeholders. Scientific maturation of messenger RNA technology has not only demonstrated rapid response capability against emerging variants but has also influenced platform selection for future vaccine development. Concurrently, improvements in protein subunit formulations, including optimized adjuvant systems, have expanded options for populations that require different safety and reactogenicity profiles. These parallel developments have created a more diversified product pipeline and widened strategic choices for manufacturers and purchasers.

Operationally, distribution networks have adapted to balance high-throughput mass vaccination campaigns with targeted, routine delivery through clinical and pharmacy channels. Policy frameworks evolved to accommodate pandemic-era emergency measures while progressively integrating lessons into standard regulatory processes. Supply chain orchestration improved through strategic partnerships with contract manufacturers and cold chain logistics providers, yet vulnerabilities remain in specialized inputs and capacity bottlenecks. Moreover, public sentiment and behavioral dynamics around booster acceptance and pediatric immunization continue to shape demand signals, necessitating ongoing engagement strategies that combine transparent evidence communication with tailored access programs.

The 2025 tariff environment catalyzing sourcing diversification, supply chain de-risking, and domestic manufacturing investment across the vaccine value chain

The imposition of tariffs and related trade measures in 2025 has added a complex layer to vaccine procurement and distribution dynamics, influencing cost profiles, sourcing strategies, and operational planning. Tariff changes affected inputs across the value chain, including specialized raw materials, single-use manufacturing components, and packaging supplies that are critical to sterile production. These adjustments prompted procurement teams to reassess supplier portfolios, seek alternative sourcing strategies, and increase emphasis on nearshoring or regional manufacturing partnerships to reduce exposure to cross-border cost volatility.

In response to heightened tariff risk, supply chain managers intensified supplier qualification processes and pursued contractual protections to insulate production continuity. Cold chain logistics providers and contract manufacturers recalibrated pricing models to reflect the incremental costs and administrative burdens associated with cross-border movements. At the same time, health systems and public purchasers evaluated procurement models with more pronounced scrutiny on total landed cost, lead times, and supply guarantees. The tariff landscape also incentivized investment in domestic fill-and-finish capacity and partnerships that prioritized geographic diversification, thereby improving strategic resilience but requiring capital allocation and longer-term planning.

A multi-dimensional segmentation perspective connecting platform science, dosage strategy, delivery route, packaging, distribution channels, end-user cohorts, and procurement models

A granular segmentation framework clarifies where product development, delivery strategies, and commercial approaches must be tailored to meet heterogeneous needs. Based on Vaccine Technology, distinctions among Inactivated, mRNA, and Protein Subunit platforms matter because each pathway demands different development timelines, manufacturing footprints, and cold chain capabilities; notably, Protein Subunit vaccines are further delineated between Adjuvanted and Non Adjuvanted formulations, which influence immunogenicity profiles and target population suitability. Based on Dosage Regimen, differences across Booster Dose, Single Dose, and Two Dose strategies drive programmatic design, influence adherence considerations, and alter supply forecasting horizons for procurement teams. Based on Application Route, the choice between Intramuscular and Intranasal delivery defines administration infrastructure needs and can affect acceptance rates among specific populations.

Further segmentation based on Packaging Type-Prefilled Syringe versus Vial-has operational implications for wastage rates, administration speed in mass clinics, and cold chain volume planning. Distribution Channel segmentation spanning Clinic, Hospital, and Pharmacy underscores the necessity of channel-specific engagement models and reimbursement considerations. End User segmentation across Adolescent, Adult, and Child cohorts requires tailored clinical evidence packages, safety communications, and dosing strategies to achieve uptake targets. Finally, Procurement Model segmentation between Government Procurement and Private Purchase shapes pricing negotiations, contracting structures, and access pathways, thereby influencing how manufacturers structure commercial offers and manage channel partnerships. Together, these segmentation lenses enable stakeholders to match product attributes to operational realities and population needs.

How differentiated regional policy frameworks, manufacturing capacity, and distribution models are shaping targeted approaches to COVID-19 vaccine access and program execution

Regional dynamics continue to exert significant influence on vaccine policy, distribution infrastructure, and commercial approaches, and recognizing these differences is essential to effective strategy formation. In the Americas, large public procurement programs coexist with substantial private demand through clinical and pharmacy channels, leading to a dual-track distribution model that emphasizes flexible supply agreements and robust cold chain logistics. The regulatory environment favors established emergency authorization mechanisms and progressive alignment toward standardized post-market surveillance practices, while public health campaigns increasingly focus on booster outreach and pediatric dosing strategies.

In Europe, Middle East & Africa, the landscape is more heterogeneous, with advanced regulatory systems in some markets and capacity constraints in others. This diversity drives strategies that combine regional manufacturing hubs, targeted deployment programs, and tailored financing mechanisms to improve access. Public-private partnerships and international procurement consortia play a pivotal role in addressing inequities and logistical gaps. In Asia-Pacific, rapid manufacturing scale-up capabilities, a growing contract manufacturing ecosystem, and diverse regulatory timelines create both opportunities and complexity for market entrants. Regional players emphasize supply reliability, competitive pricing, and the ability to support large-scale immunization campaigns, while also navigating evolving local regulatory expectations and distribution modalities. Across all regions, collaboration between policymakers, manufacturers, and service providers remains a critical enabler of effective vaccine program implementation.

Strategic behaviors among vaccine developers, contract manufacturers, and logistics partners revealing collaboration, modular capacity expansion, and channel diversification

Companies operating in the COVID-19 vaccine space demonstrate a range of strategic postures, from platform innovation and incremental formulation improvements to capacity-focused partnerships and diversified commercial channels. Leading biopharmaceutical firms have continued to invest in next-generation vaccine platforms and adjuvant systems to widen their addressable populations and improve safety and tolerability profiles. At the same time, contract manufacturing organizations and cold chain logistics specialists have strengthened alliances with vaccine developers to expand fill-and-finish throughput and reduce bottlenecks that previously constrained rapid deployment.

Strategic collaboration has become a dominant theme, with alliances spanning clinical research universities, biotech innovators, and global distribution partners to accelerate candidate progression while managing cost and risk. Some companies have prioritized modular manufacturing designs that facilitate rapid switching between vaccine types, whereas others have invested in regional production footprints to mitigate trade-related disruptions. Commercial strategies increasingly blend direct government contracting with pharmacy and clinic channel engagement, supported by targeted educational campaigns to address hesitancy. Overall, the competitive dynamic rewards organizations that can combine scientific agility with operational scalability and credible, transparent stakeholder communication.

Practical strategic moves for vaccine stakeholders to enhance manufacturing flexibility, cold chain visibility, regulatory engagement, and channel-specific access approaches

Industry leaders can accelerate impact by aligning strategic investments with operational realities and public health objectives. First, prioritizing flexible manufacturing capacity-capable of handling multiple platforms and dose configurations-reduces time-to-deployment for novel formulations and supports rapid response to emergent variants. Second, strengthening end-to-end cold chain visibility through digital tracking and integrated logistics partnerships minimizes wastage and improves allocation decisions, particularly in contexts with constrained storage infrastructure. Third, cultivating regulatory engagement that focuses on clear evidence requirements for specific populations, such as adolescents and children, streamlines approval pathways and bolsters program confidence.

In parallel, adopting differentiated channel strategies that recognize the distinct roles of clinics, hospitals, and pharmacies ensures broader access while addressing local administration preferences. Investment in tailored risk communication and community engagement programs can improve booster acceptance and sustain immunization momentum. Finally, exploring procurement structures that combine long-term supply commitments with options for private purchase supports both public health objectives and commercial sustainability. Together, these actions enhance resilience, support equitable access, and create a more predictable operating environment for vaccine stakeholders.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory and clinical evidence review, and supply chain case study triangulation

This research synthesizes primary and secondary evidence to construct a comprehensive view of the COVID-19 vaccine landscape. Primary inputs included structured interviews with stakeholders across manufacturing, logistics, regulatory affairs, and public health administration, providing firsthand perspectives on operational challenges and strategic responses. Secondary inputs encompassed peer-reviewed literature, public regulatory filings, clinical trial registries, and industry technical reports to ensure factual grounding and cross-validation of claims. Data on distribution and procurement practices were triangulated through supply chain process mapping and case studies that highlight real-world implementation lessons.

Analytical methods combined qualitative thematic analysis with comparative scenario assessment to surface risks and identify resilience strategies. The methodology emphasized transparency in sourcing and reproducibility in approach, with clear documentation of interview protocols, inclusion criteria for secondary sources, and the analytical frameworks used to synthesize findings. Where appropriate, the research incorporated sensitivity checks to evaluate how changes in trade policy, variant emergence, or public acceptance could alter operational priorities. This mixed-method approach ensures that insights reflect both empirical evidence and pragmatic perspectives from practitioners.

A forward-looking synthesis that underscores the necessity of aligning scientific innovation, resilient operations, and collaborative policy to secure long-term vaccine program success

As the global community moves beyond the initial pandemic emergency phase, the COVID-19 vaccine ecosystem is settling into a more complex, mature era where scientific innovation, operational excellence, and policy coherence determine long-term outcomes. The interplay of novel platforms, evolving dosage strategies, and diversified delivery models offers multiple pathways to improve population protection while addressing equity and access concerns. However, realizing these opportunities requires continued investment in scalable manufacturing, smarter procurement practices, and sustained public engagement to maintain confidence and uptake.

Looking ahead, the capacity to integrate scientific advances with resilient supply chains and adaptive regulatory strategies will define organizational success. Stakeholders that proactively manage tariff and trade risks, invest in modular production capabilities, and tailor approaches to regional realities will be better positioned to deliver reliable access to vaccines. Ultimately, the sector's progress will depend on collaborative problem-solving across public and private actors to align incentives, share capacity, and prioritize interventions that maximize public health benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of bivalent and multivalent vaccine formulations targeting emerging SARS-CoV-2 variants to enhance immune coverage
  • 5.2. Rising emphasis on intranasal and mucosal vaccine candidates to improve transmission blockage and patient compliance
  • 5.3. Strategic partnerships between biotech startups and big pharma for accelerated vaccine manufacturing capacity scaling
  • 5.4. Regulatory milestone of conditional approvals for next-generation COVID vaccines in key global markets
  • 5.5. Growing investor interest in thermostable mRNA vaccine platforms to facilitate distribution in low-resource settings
  • 5.6. Increased focus on pediatric and maternal vaccination programs amid changing immunity profiles and dosing guidelines
  • 5.7. Development of pan-coronavirus vaccine research initiatives aimed at broad protection against future zoonotic outbreaks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Vaccines Market, by Vaccine Technology

  • 8.1. Inactivated
  • 8.2. mRNA
  • 8.3. Protein Subunit
    • 8.3.1. Adjuvanted
    • 8.3.2. Non Adjuvanted

9. COVID-19 Vaccines Market, by Dosage Regimen

  • 9.1. Booster Dose
  • 9.2. Single Dose
  • 9.3. Two Dose

10. COVID-19 Vaccines Market, by Application Route

  • 10.1. Intramuscular
  • 10.2. Intranasal

11. COVID-19 Vaccines Market, by Packaging Type

  • 11.1. Prefilled Syringe
  • 11.2. Vial

12. COVID-19 Vaccines Market, by Distribution Channel

  • 12.1. Clinic
  • 12.2. Hospital
  • 12.3. Pharmacy

13. COVID-19 Vaccines Market, by End User

  • 13.1. Adolescent
  • 13.2. Adult
  • 13.3. Child

14. COVID-19 Vaccines Market, by Procurement Model

  • 14.1. Government Procurement
  • 14.2. Private Purchase

15. COVID-19 Vaccines Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. COVID-19 Vaccines Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. COVID-19 Vaccines Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Pfizer Inc.
    • 18.3.2. Moderna, Inc.
    • 18.3.3. AstraZeneca PLC
    • 18.3.4. Johnson & Johnson Services Inc.
    • 18.3.5. China National Pharmaceutical Group Co., Ltd.
    • 18.3.6. Sinovac Biotech Ltd.
    • 18.3.7. Serum Institute of India Pvt. Ltd.
    • 18.3.8. Novavax, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRIVATE PURCHASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 312. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 313. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 314. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 315. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GCC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2018-2024 (USD MILLION)
  • TABLE 324. GCC COVID-19 VACCINES MARKET SIZE, BY PROCUREMENT MODEL, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL,